Follow-up study of gene therapy in the other eye
This study looks at the safety and effectiveness of giving the gene therapy treatment to your other eye, after you've already had it in one eye and been followed for a year. It may help improve vision in the untreated eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already received the study treatment in one eye and completed 1 year of follow-up.
- You are between 8 and 45 years old.
- Your vision in the study eye is not better than 20/32 on a standard eye chart.
- If you can become pregnant, you must have a negative pregnancy test and agree to use birth control during the study and for 12 months after treatment.
- You must be willing to sign a consent form and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
Hear when a new Inherited Retinal Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.